核心人员离职、出海受挫,“ADC一哥”荣昌生物陷多事之秋

子弹财经
22 Feb

进入2025年,荣昌生物便踏入了“多事之秋”,被一连串的负面消息所笼罩。2月伊始,荣昌生物执行董事兼核心技术人员何如意突然宣布辞职,在生物医药行业激起千层浪。何如意在行业内声名赫赫,其拥有丰富的专业知识和深厚的技术积累,一直是荣昌生物发展的重要助力。他的离职,不仅让公司技术研发布局面临调整,也引发了外界诸多猜测和不安。紧接着,辉瑞发布2024年财报中的其中一项内容,再次将荣昌生物推至风口浪尖。财报...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10